Spectrum: Autism Research News

Roche’s gene therapy drug Rugonersen boosts expression of the protein missing in the syndrome in mice and monkeys, but whether it works in people remains to be seen.

Many brain regions develop differently between people with 22q11.2 duplications and deletions, and those trajectories also vary with a person’s diagnosis.

What these genes do and how they affect autism depends on when in development they’re studied, despite what classic ‘gene ontology’ analyses say.

Here is a roundup of news and research for the week of 15 August.

Here is a roundup of news and research for the week of 8 August.

Interim results from the previously paused trial suggest that doses of the experimental gene therapy drug GTX-102 are well tolerated in children with the autism-linked condition.

Through a website called Stories of Women in Neuroscience, Nancy Padilla-Coreano aims to shift biases in the field, one conversation at a time.

People’s brains have a larger network of inhibitory interneurons than mouse brains do, according to a new study. Changes to that network could contribute to autism or other conditions, says lead investigator Moritz Helmstaedter.

Deletion of the 22q11.2 chromosomal region alters the expression of numerous autism- and schizophrenia-linked genes, most of which are not contained within the deleted region, a new study suggests.

An experimental drug improves sensory sensitivities in fragile X model mice — but only if it’s administered after certain brain circuits have formed, according to a new unpublished study.